Ethanol enhances the inhibitory effect of an oral GPIIB/IIIa antagonist on human platelet function

Journal of Laboratory and Clinical Medicine

Volumn 140, Issue 6, 2002, Pages 391-397

  Rand, Margaret L ^a,b,c   Jakubowski, Joseph A ^a,b,c   Fisher, Matthew J ^a,b,c   Chahil, Amar ^a,b,c   Kinlough Rathbone, Raelene L ^a,b,c   Packham, Marian A ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0036909085     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2002.129311     Document Type: Article

References (41)

1. Packham MA, Mustard JF. Role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986;23:8-26.
2. Kinlough-Rathbone RL, Mustard JF. Synergism of agonists. In: Holmsen H, ed. Platelet Responses and Metabolism, vol 1. Boca Raton, Fla: CRC Press, 1986:193-207.
3. Ware JA, Smith M, Salzman EW. Synergism of platelet-aggregating agents: Role of elevation of cytoplasmic calcium. J Clin Invest 1987;80:267-71.
4. IIbβ3 and platelet function. Thromb Haemost 1997;78:96-100.
5. Coller BS. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997;78:730-5.
6. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-44.
7. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139:S38-45.
8. Van de Werf F. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. Thromb Haemost 1997;78:210-3.
9. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at 6 months. Lancet 1994;343:881-6.
10. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al, for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;77:1045-51.
11. Tcheng JE, The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
12. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
13. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, et al, for the TIMI 12 Investigators. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998:97:340-9.
14. Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud ARZ, Broderick TM, Abbottsmith CW, et al, for the ORBIT Trial Investigators. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial. Circulation 1998;98:1268-78.
15. Chew DP, Bhatt DL, Sapp H, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-6.
16. Fisher MJ, Gunn B, Harms CS, Kline AD, Mullaney JT, Nunes A, et al. Non-peptide RGD surrogates which mimic a Gly-Asp β-turn: Potent antagonists of platelet glycoprotein IIb-IIIa. J Med Chem 1997;40:2085-101.
17. Rand ML, Packham MA, Kinlough-Rathbone RL, Mustard JF. Effects of ethanol on pathways of platelet aggregation in vitro. Thromb Haemost 1988;59:383-7.
18. Rand ML, Vickers JD, Kinlough-Rathbone RL, Packham MA, Mustard JF. Thrombin-induced inositol trisphosphate production by rabbit platelets is inhibited by ethanol. Biochem J 1988;251:279-84.
19. Jakubowski JA, Vaillancourt R, Deykin D. Interaction of ethanol, prostacyclin, and aspirin in determining human platelet reactivity in vitro. Arteriosclerosis 1988;8:436-41.
20. Rand ML, Gross PL, Jakowec DM, Packham MA, Mustard JF. In vitro effects of ethanol on rabbit platelet aggregation, secretion of granule contents, and cyclic AMP levels in the presence of prostacyclin. Thromb Haemost 1989;61:254-8.
21. Rand ML, DaCosta SM, Chahil A, Kinlough-Rathbone RL. Combined inhibitory effects of ethanol and adenosine on the responses of rabbit platelets to thrombin. Alcohol Clin Exp Res 1995;19:1279-85.
22. Théroux P. Antiplatelet therapy: Do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J 1997;134:S62-70.
23. Davies JA, Essien E, Cazenave J-P, Kinlough-Rathbone RL, Gent M, Mustard JF. The influence of red blood cells on the effects of aspirin or sulphinpyrazone on platelet adherence to damaged rabbit aorta. Br J Haematol 1979;42:283-91.
24. 2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987;70:647-51.
25. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989;62:968-76.
26. 2+ on GP IIb-IIIa interactions with Integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
27. Rebello SS, Huang J, Saito K, Lucchesi BR. In vivo efficacy of SM-20302, a GP IIb/IIIa receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterioscler Thromb Vasc Biol 1998;18:954-60.
28. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: Implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-21.
29. 2. Thromb Res 1997;88:109-25.
30. Joist JH, Dolezel G, Lloyd JV, Kinlough-Rathbone RL, Mustard JF. Platelet factor-3 availability and the platelet release reaction. J Lab Clin Med 1974;84:474-82.
31. Schroit AJ, Zwaal RFA. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta 1991;1071:313-29.
32. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-74.
33. Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998;90:247-58.
34. Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998;79:383-8.
35. Keularts IMLW, Béguin S, de Zwaan C, Hemker HC. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb Haemost 1998;80:370-1.
36. Nguyen A, Gemmell CH, Yeo EL, Packham MA, Rand ML. Ethanol inhibits thrombin-induced secretion of the contents of human platelet dense and α-granules and lysosomes. Thromb Haemost 1998;80:662-7.
37. Umemura K, Kondo K, Ikeda Y, Nakashima M. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. Thromb Haemost 1997;78:1381-4.
38. Rupprecht HJ, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-52.
39. Negrescu EV, Grunberg B, Kratzer MAA, Lorenz R, Siess W. Interaction of antiplatelet drugs in vitro: Aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside. Cardiovasc Drugs Ther 1995;9:619-29.
40. 1 reduce rabbit and human platelet adherence without inhibiting serotonin release from adherent platelets. Thromb Res 1979;15:273-9.
41. Kinlough-Rathbone RL, Cazenave J-P, Packham MA, Mustard JF. Effect of inhibitors of the arachidonate pathway on the release of granule contents from rabbit platelets adherent to collagen. Lab Invest 1980;42:28-34.